Immunovant (IMVT) Net Income towards Common Stockholders Growth (3y) (2021 - 2026)
Immunovant (IMVT) Net Income towards Common Stockholders Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 71.02% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.89% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.99% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -38.56% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 37.44% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 62.15% |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | -27.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.49% |
| Mar 31, 2026 | -35.50% |
| Dec 31, 2025 | -20.50% |
| Sep 30, 2025 | -38.20% |
| Jun 30, 2025 | -44.02% |
| Mar 31, 2025 | -31.17% |
| Dec 31, 2024 | -38.99% |
| Sep 30, 2024 | -42.51% |
| Jun 30, 2024 | -41.95% |
| Mar 31, 2024 | -38.81% |
| Dec 31, 2023 | -17.40% |
| Sep 30, 2023 | -41.31% |
| Jun 30, 2023 | -40.41% |
| Mar 31, 2023 | -42.47% |
| Dec 31, 2022 | -77.55% |
| Sep 30, 2022 | -48.44% |
| Jun 30, 2022 | -26.17% |
| Mar 31, 2022 | -73.50% |
| Dec 31, 2021 | -67.23% |